PositiveID (PSID) Receives Nucleic Acids From the Centers for Disease Control and Prevention (CDC) Influenza Division to Develop a Diagnostic Assay to Detect H5N1 Avian Flu
DELRAY BEACH, Fla., March 28, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense industry, announced today that it has received material from the U.S. Centers for Disease Control and Prevention's (CDC) Influenza Division-National Center for Immunization and Respiratory Diseases to develop a diagnostic assay to detect Influenza A H5N1, also known as avian flu. This assay will provide a test result in less than 30 minutes at the point of care, and is expected to be available for the upcoming flu season for diagnostic and surveillance applications.